Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families

Genes Chromosomes and Cancer

Volumn 51, Issue 10, 2012, Pages 933-948

  Kouprina, Natalay ^a   Lee, Nicholas C O ^a   Pavlicek, Adam ^b   Samoshkin, Alexander ^a   Kim, Jung Hyun ^a   Lee, Hee Sheung ^a   Varma, Sudhir ^a   Reinhold, William C ^a   Otstot, John ^c   Solomon, Greg ^c   Davis, Sean ^a   Meltzer, Paul S ^a   Schleutker, Johanna ^d,e   Larionov, Vladimir ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PFIZER INC   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d UNIVERSITY OF TURKU   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

ARTICLE; CANCER CELL; CANCER SUSCEPTIBILITY; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; GENE; GENE CLUSTER; GENE EXPRESSION; GENE LOCUS; GENOME; HPCX1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SEGMENTAL DUPLICATION;

AUTOANTIGENS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, X; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FAMILY; FEMALE; GENETIC LINKAGE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; RECOMBINATION, GENETIC; SACCHAROMYCES CEREVISIAE; SEGMENTAL DUPLICATIONS, GENOMIC;

EID: 84864781036     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21977     Document Type: Article

References (73)

1. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J Mol Biol 215: 403-410.
2. Altschul SF, Madden TL, Schaffer AA, Zhang JH, Zhang Z, Miller W, Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.
3. Arlt MF, Durkin SG, Ragland RL, Glover TW. 2006. Common fragile sites as targets for chromosome rearrangements. DNA Repair 5: 1126-1135.
4. Baffoe-Bonnie AB, Smith JB, Stephan DA, Schleutker J, Carpten JD, Kainu T, Gillanders EM, Matikainen M, Teslovich TM, Tammela T, Sood R, Balshem AM, Scarborough SD, Xu JF, Isaacs WB, Trent JM, Kallioniemi OP, Bailey-Wilson JE. 2005. A major locus for hereditary prostate cancer in Finland: Localization by linkage disequilibrium of a haplotype in the HPCX region. Hum Genet 117: 307-316.
5. Bailey JA, Gu ZP, Clark RA, Reinert K, Samonte RV, Schwartz S, Adams MD, Myers EW, Li PW, Eichler EE. 2002. Recent segmental duplications in the human genome. Science 297: 1003-1007.
6. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate-A practical and powerful approach to multiple testing. J R Stat Soc B Met 57: 289-300.
7. Bochum S, Paiss T, Vogel W, Herkommer K, Hautmann R, Haeussler J. 2002. Confirmation of the prostate cancer susceptibility locus HPCX in a set of 104 German prostate cancer families. Prostate 52: 12-19.
8. Bray N, Pachter L. 2004. MAVID: Constrained ancestral alignment of multiple sequences. Genome Res 14: 693-699.
9. Brown WM, Lange EM, Chen H, Zheng SL, Chang B, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Xu J, Cooney KA. 2004. Hereditary prostate cancer in African American families: Linkage analysis using markers that map to five candidate susceptibility loci. Br J Cancer 90: 510-514.
10. Chen YT, Rettig WJ, Yenamandra AK, Kozak CA, Chaganti RSK, Posner JB, Old LJ. 1990. Cerebellar degeneration-related antigen-A highly conserved neuroectodermal marker mapped to chromosomes-X in human and mouse. Proc Natl Acad Sci USA 87: 3077-3081.
11. Colloca G, Venturino A. 2011. The evolving role of familial history for prostate cancer. Acta Oncol 50: 14-24.
12. de Kovel CG, Hol FA, Heister JG, Willemen JJ, Sandkuijl LA, Franke B, Padberg GW. 2004. Genomewide scan identifies susceptibility locus for dyslexia on Xq27 in an extended Dutch family. J Med Genet 41: 652-657.
13. Dropcho EJ, Chen YT, Posner JB, Old LJ. 1987. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA 84: 4552-4556.
14. Esteller M. 2011. Non-coding RNAs in human disease. Nat Rev Genet 12: 861-874.
15. Farnham JM, Camp NJ, Swensen J, Tavtigian SV, Albright LAC. 2005. Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet 116: 179-185.
16. Furneaux HM, Wong E, Posner JB. 1990. Isolation of cDNA clones encoding the major Yo paraneoplastic antigen. Neurology 40: 166.
17. Gillanders EM, Xu JF, Chang BL, Lange EM, Wiklund F, Bailey-Wilson JE, Baffoe-Bonnie A, Jones M, Gildea D, Riedesel E, Albertus J, Isaacs SD, Wiley KE, Mohai CE, Matikainen MP, Tammela TLJ, Zheng SL, Brown WM, Rokman A, Carpten JD, Meyers DA, Walsh PC, Schleutker J, Gronberg H, Cooney KA, Isaacs WB, Trent JM. 2004. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer I 96: 1240-1247.
18. Gotter AL, Nimmakayalu MA, Jalali GR, Hacker AM, Vorstman J, Duffy DC, Medne L, Emanuel BS. 2007. A palindrome-driven complex rearrangement of 22q11.2 and 8q24.1 elucidated using novel technologies. Genome Res 17: 470-481.
19. Gouy M, Guindon S, Gascuel O. 2010. SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol 27: 221-224.
20. Goydos JS, Patel M, Shih WC. 2001. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J Surg Res 98: 76-80.
21. Katoh K, Toh H. 2010. Parallelization of the MAFFT multiple sequence alignment program. Bioinformatics. 26: 1899-1900.
22. Katoh K, Kuma K, Toh H, Miyata T. 2005. MAFFT version 5: Improvement in accuracy of multiple sequence alignment. Nucleic Acids Res 33: 511-518.
23. Kibel AS, Faith DA, Bova GS, Isaacs WB. 2003. Xq27-28 deletions in prostate carcinoma. Genes Chromosomes Cancer 37: 381-388.
24. Kidd JM, Cooper GM, Donahue WF, Hayden HS, Sampas N, Graves T, Hansen N, Teague B, Alkan C, Antonacci F, Haugen E, Zerr T, Yamada NA, Tsang P, Newman TL, Tuzun E, Cheng Z, Ebling HM, Tusneem N, David R, Gillett W, Phelps KA, Weaver M, Saranga D, Brand A, Tao W, Gustafson E, McKernan K, Chen L, Malig M, Smith JD, Korn JM, McCarroll SA, Altshuler DA, Peiffer DA, Dorschner M, Stamatoyannopoulos J, Schwartz D, Nickerson DA, Mullikin JC, Wilson RK, Bruhn L, Olson MV, Kaul R, Smith DR, Eichler EE. 2008. Mapping and sequencing of structural variation from eight human genomes. Nature 453: 56-64.
25. Kouprina N, Larionov V. 2006. Innovation-TAR cloning: Insights into gene function, long-range haplotypes and genome structure and evolution. Nat Rev Genet 7: 805-812.
26. Kouprina N, Larionov V. 2008. Selective isolation of genomic loci from complex genomes by transformation-associated recombination cloning in the yeast Saccharomyces cerevisiae. Nat Protoc 3: 371-377.
27. Kouprina N, Mullokandov M, Rogozin IB, Collins NK, Solomon G, Otstot J, Risinger JI, Koonin EV, Barrett JC, Larionov V. 2004. The SPANX gene family of cancer/testis-specific antigens: Rapid evolution and amplification in African great apes and hominids. Proc Natl Acad Sci USA 101: 3077-3082.
28. Kouprina N, Pavlicek A, Noskov VN, Solomon G, Otstot J, Isaacs W, Carpten JD, Trent JM, Schleutker J, Barrett JC, Jurka J, Larionov V. 2005. Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. Genome Res 15: 1477-1486.
29. Kouprina N, Noskov VN, Pavlicek A, Collins NK, Bortz PDS, Ottolenghi C, Loukinov D, Goldsmith P, Risinger JI, Kim JH, Westbrook VA, Solomon G, Sounders H, Herr JC, Jurka J, Lobanenkov V, Schlessinger D, Larionov V. 2007a. Evolutionary diversification of SPANX-N sperm Protein gene structure and expression. PloS One 2: E359.
30. Kouprina N, Noskov VN, Solomon G, Otstot J, Isaacs W, Xu J, Schleutker J, Larionov V. 2007b. Mutational analysis of SPANX genes in families with X-linked prostate cancer. Prostate 67: 820-828.
31. Lange EM, Chen H, Brierley K, Perrone EE, Bock CH, Gillanders E, Ray ME, Cooney KA. 1999. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin Cancer Res 5: 4013-4020.
32. Lucas S, De Smet C, Arden KC, Viars CS, Lethe B, Lurquin C, Boon T. 1998. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 58: 743-752.
33. Lutke-Holzik MF, Rapley EA, Hoekstra HJ, Sleijfer DT, Nolte IM, Sijmons RH. 2004. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol 5: 363-371.
34. Maher BH, Kerr M, Cox HC, MacMillan JC, Brimage PJ, Esposito T, Gianfrancesco F, Haupt LM, Nyholt DR, Lea RA, Griffiths LR. 2012. Confirmation that Xq27 and Xq28 are susceptibility loci for migraine in independent pedigrees and a case-control cohort. Neurogenetics 13: 97-101.
35. Mattila H, Schindler M, Isotalo J, Ikonen T, Vihinen M, Oja H, Tammela TLJ, Wahlfors T, Schleutker J. 2011. NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene. BMC Cancer 11: 327.
36. Mefford HC, Eichler EE. 2009. Duplication hotspots, rare genomic disorders, and common disease. Curr Opin Genet Dev 19: 196-204.
37. Morganti G, Gianferrari L, Cresseri A. 1956. Recherches clinico-statistiques et genetiques sur les neoplasies de la prostate. Acta Genet 6: 304-305.
38. Morgenstern B. 2004. DIALIGN: Multiple DNA and protein sequence alignment at BiBiServ. Nucleic Acids Res 32: W33-W36.
39. Nagasaki K, Schem C, von Kaisenberg C, Biallek M, Rosel F, Jonat W, Maass N. 2003. Leucine-zipper protein, LDOC1, inhibits NF-kappaB activation and sensitizes pancreatic cancer cells to apoptosis. Int J Cancer 105: 454-458.
40. Neuhausen SL, Farnham JM, Kort E, Tavtigian SV, Skolnick MH, Cannon-Albright LA. 1999. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. Hum Mol Genet 8: 2437-2442.
41. Nicholas KB, Nicholas HB Jr, Deerfield DW II. 1997. GeneDoc: Analysis and visualization of genetic variation, EMBNEW. NEWS 4: 14.
42. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao XH, Jing XJ, Wang XJ, Siddiqui J, Wei JT, Robinson D, Iyer HK, Palanisamy N, Maher CA, Chinnaiyan AM. 2011. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29: 742-749.
43. Ren XP, Wu JH, Wang XH, Sartor MA, Qian J, Jones K, Nicolaou P, Pritchard TJ, Fan GC. 2009. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119: 2357-2366.
44. Rettig WJ, Chen YT, Yenamandra AK, Chaganti RSK, Dropcho EJ, Posner JB, Old LJ. 1987. Assignment of the cerebellar degeneration-related autoantigen CDR to human chromosome X. Abstract. Cytogenet. Cell Genet 46: 681.
45. Rice P, Longden I, Bleasby A. 2000. EMBOSS: The European molecular biology open software suite. Trends Genet 16: 276-277.
46. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. 2011. Integrative genomics viewer. Nat Biotechnol 29: 24-26.
47. Rubin MA, De Marzo AM. 2004. Molecular genetics of human prostate cancer. Mod Pathol 17: 380-388.
48. Schaid DJ. 2004. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13: 103-121.
49. Schleutker J, Matikainen M, Smith J, Koivisto P, Baffoe-Bonnie A, Kainu T, Gillanders E, Sankila R, Pukkala E, Carpten J, Stephan D, Tammela T, Brownstein M, Bailey-Wilson J, Trent J, Kallioniemi OP. 2000. A genetic epidemiological study of hereditary prostate cancer. HPC in Finland: Frequent HPCX linkage in families with late-onset disease. Clin Cancer Res 6: 4810-4815.
50. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, Walker M, Chi MY, Navin N, Lucito R, Healy J, Hicks J, Ye K, Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M. 2004. Large-scale copy number polymorphism in the human genome. Science 305: 525-528.
51. Shaikh TH, Gai XW, Perin JC, Glessner JT, Xie HB, Murphy K, O'Hara R, Casalunovo T, Conlin LK, D'Arcy M, Frackelton EC, Geiger EA, Haldeman-Englert C, Imielinski M, Kim CE, Medne L, Annaiah K, Bradfield JP, Dabaghyan E, Eckert A, Onyiah CC, Ostapenko S, Otieno FG, Santa E, Shaner JL, Skraban R, Smith RM, Elia J, Goldmuntz E, Spinner NB, Zackai EH, Chiavacci RM, Grundmeier R, Rappaport EF, Grant SFA, White PS, Hakonarson H. 2009. High-resolution mapping and analysis of copy number variations in the human genome: A data resource for clinical and research applications. Genome Res 19: 1682-1690.
52. Shoemaker RH. 2006. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
53. Slavotinek A, Lee SS, Hamilton SP. 2005. A family with X-linked anophthalmia: Exclusion of SOX3 as a candidate gene. Am J Med Genet 138A: 89-94.
54. Solomon NM, Ross SA, Morgan T, Belsky JL, Hol FA, Karnes PS, Hopwood NJ, Myers SE, Tan AS, Warne GL, Forrest SM, Thomas PQ. 2004. Array comparative genomic hybridization analysis of boys with X linked hypopituitarism identifies a 3.9 Mb duplicated critical region at Xq27 containing SOX3. J Med Genet 41: 669-678.
55. Stankiewicz P, Lupski JR. 2006. The genomic basis of disease, mechanisms and assays for genomic disorders. Genome Dyn 1: 1-16.
56. Stankiewicz P, Lupski JR. 2010. Structural variation in the human genome and its role in disease. Annu Rev Med 61: 437-455.
57. Stephan DA, Howell GR, Teslovich TM, Coffey AJ, Smith L, Bailey-Wilson JE, Malechek L, Gildea D, Smith JR, Gillanders EM, Schleutker J, Hu P, Steingruber HE, Dhami P, Robbins CM, Makalowska I, Carpten JD, Sood R, Mumm S, Reinbold R, Bonner TI, Baffoe-Bonnie A, Bubendorf L, Heiskanen M, Kallioneimi OP, Baxevanis AD, Joseph SS, Zucchi I, Burk RD, Isaacs W, Ross MT, Trent JM. 2002. Physical and transcript map of the hereditary prostate cancer region at Xq27. Genomics 79: 41-50.
58. Van Wynsberghe PM, Chan SP, Slack FJ, Pasquinelli AE. 2011. Analysis of microRNA expression and function. Methods Cell Biol 106: 219-252.
59. Varghese JS, Easton DF. 2010. Genome-wide association studies in common cancers-What have we learnt? Curr Opin Genet Dev 20: 201-209.
60. Verhage BA, Kiemeney LA. 2003. Genetic susceptibility to prostate cancer: A review. Fam Cancer 2: 57-67.
61. Vincent JB, Melmer G, Bolton PF, Hodgkinson S, Holmes D, Curtis D, Gurling HM. 2005. Genetic linkage analysis of the X chromosome in autism, with emphasis on the fragile X region. Psychiatr Genet 15: 83-90.
62. Vitek WS, Pagidas K, Gu G, Pepperell JR, Simpson JL, Tantravahi U, Plante BJ. 2012. Xq;autosome translocation in POF: Xq27.2 deletion resulting in haploinsufficiency for SPANX. J Assist Reprod Genet 29: 63-66.
63. Wang KC, Chang HY. 2011. Molecular mechanisms of long noncoding RNAs. Mol Cell 43: 904-914.
64. Wang ZQ, Zhang YN, Liu HC, Salati E, Chiriva-Internati M, Lim SH. 2003. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood 101: 955-960.
65. Westbrook VA, Diekman AB, Klotz KL, Khole VV, von Kap-Herr C, Golden WL, Eddy RL, Shows TB, Stoler MH, Lee CYG, Flickinger CJ, Herr JC. 2000. Spermatid-specific expression of the novel X-linked gene product SPAN-X localized to the nucleus of human spermatozoa. Biol Reprod 63: 469-481.
66. Westbrook VA, Diekman AB, Naaby-Hansen S, Coonrod SA, Klotz KL, Thomas TS, Norton EJ, Flickinger CJ, Herr JC. 2001. Differential nuclear localization of the cancer/testis-associated protein, SPAN-X/CTp11, in transfected cells and in 50% of human spermatozoa. Biol Reprod 64: 345-358.
67. Westbrook VA, Schoppee PD, Diekman AB, Klotz KL, Allietta M, Hogan KT, Slingluff CL, Patterson JW, Frierson HF, Irvin WP, Flickinger CJ, Coppola MA, Herr JC. 2004. Genomic organization, incidence, and localization of the SPAN-X family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res 10: 101-112.
68. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Gronberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J. 1998. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20: 175-179.
69. Xu J, Gillanders EM, Isaacs SD, Chang BL, Wiley KE, Zheng SL, Jones M, Gildea D, Riedesel E, Albertus J, Freas-Lutz D, Markey C, Meyers DA, Walsh PC, Trent JM, Isaacs WB. 2003. Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate 57: 320-325.
70. Yaspan BL, McReynolds KM, Elmore JB, Breyer JP, Bradley KM, Smith JR. 2008. A haplotype at chromosome Xq27.2 confers susceptibility to prostate cancer. Hum Genet 123: 379-386.
71. Zendman AJW, Cornelissen IMHA, Weidle UH, Ruiter DJ, van Muijen GNP. 1999. CTp11, a novel member of the family of human cancer/testis antigens. Cancer Res 59: 6223-6229.
72. Zendman AJ, Zschocke J, van Kraats AA, de Wit NJ, Kurpisz M, Weidle UH, Ruiter DJ, Weiss EH, van Muijen GN. 2003. The human SPANX multigene family: Genomic organization, alignment and expression in male germ cells and tumor cell lines. Gene 309: 125-133.
73. Zhu HW, Shang DD, Sun M, Choi SJ, Liu Q, Hao JJ, Figuera LE, Zhang F, Choy KW, Ao Y, Liu Y, Zhang XL, Yue FZ, Wang MR, Jin L, Patel PI, Jing T, Zhang X. 2011. X-linked congenital hypertrichosis syndrome is associated with interchromosomal insertions mediated by a human-specific palindrome near SOX3. Am J Hum Genet 88: 819-826.